|Bid||5.84 x 1200|
|Ask||6.01 x 4000|
|Day's Range||5.70 - 6.03|
|52 Week Range||5.24 - 13.41|
|Beta (3Y Monthly)||3.74|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 7, 2019 - Feb 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.00|
HENDERSON, NV / ACCESSWIRE / November 14, 2018 / After a tough year, the prospect that a split congress could be a good thing for healthcare stocks is causing some investors to look again at several smaller ...
Cara Therapeutics (CARA) is a clinical-stage biotechnology company developing new chemical entities for managing pain and pruritus. Cara Therapeutics reported EPS of -$0.52 on revenue of $2.87 million in the second quarter.
Investors slowly backed away from the stock in anticipation of a big data release, which ended up landing with a thud later in the month.
NEW YORK, Nov. 07, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that the following presentations by
Anyone researching ImmunoGen Inc (NASDAQ:IMGN) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there are Read More...
ImmunoGen (IMGN) delivered earnings and revenue surprises of 8.82% and -8.32%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Waltham, Massachusetts-based company said it had a loss of 32 cents per share. Losses, adjusted for restructuring costs, came to 31 cents per share. The results surpassed Wall Street expectations. ...
Initial Data from FORWARD II Expansion Cohort of Mirvetuximab Soravtansine with KEYTRUDA® Reported at ESMO
ImmunoGen, Inc. (NASDAQ: IMGN ) announces its next round of earnings Friday. Here is Benzinga's everything-that-matters guide for the Q3 earnings announcement. Earnings and Revenue Analysts are predicting ...
ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Preliminary Data Demonstrate Favorable Safety Profile and Encouraging Activity in Heavily Pretreated Patients with Ovarian Cancer
ImmunoGen, Inc., (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Company will host a conference call at 8:00 a.m. ET on Friday, November 2, 2018 to discuss its third quarter operating results. The call may also be accessed through the Investors section of the Company’s website, www.immunogen.com. ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.
HENDERSON, NV / ACCESSWIRE / October 15, 2018 / Below we've highlighted a few companies working on treatments for different types of cancers that could potentially create value for shareholders. One company ...
Here are a few catalysts that can dictate the directional moves of biotech stocks in the upcoming week: Conferences European Society For Medical Oncology, or ESMO, 2018 Congress – Oct. 19-23, in Munich, ...
NEW YORK, Oct. 10, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
ImmunoGen, Inc., (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that initial findings from the FORWARD II expansion cohort of mirvetuximab soravtansine in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), will be presented at the European Society for Medical Oncology (ESMO) Congress from October 19-23, 2018 in Munich, Germany. The poster will include initial safety and preliminary anti-tumor activity for 46 patients with platinum-resistant ovarian cancer (PROC), of whom 35 have medium or high folate receptor alpha (FRα) expression. Encouraging activity and favorable tolerability data from the FORWARD II dose-escalation cohort assessing mirvetuximab soravtansine in combination with KEYTRUDA in 14 heavily pre-treated patients with platinum-resistant epithelial ovarian cancer (EOC) were presented in March at the Society of Gynecologic Oncology (SGO) Annual Meeting.
Live from the floor of the New York Stock Exchange, Yahoo Finance's Jared Blikre joins Alexis Christoforous to discuss the latest market moves as Wall Street digests headlines about US-China trade relations, this morning's BLS Employment Situation report, and a barrage of earnings, from Apple to Exxon Mobil. Here's the performance of recent earnings (as of 10:45 am EDT, Friday): ~Thurs AMC SBUX Starbucks Corp 10.60% SYMC(E) Symantec Corp 6.43% MET Metlife Inc 4.41% X U.S. Steel Corporation 2.54% WU Western Union Co (THE) -0.25% CBS CBS Corporation -1.25% EOG EOG Resources -2.25% AAPL Apple Inc -6.72% KHC The Kraft Heinz Company -7.82% GERN(HB) Geron Corp -8.11% SHAK Shake Shack Inc -11.41% GPRO GoPro Inc Cl A -21.80% OLED Universal Display Corp -27.13% WTW Weight Watchers Intl -29.87% ~Fri BMO CVX Chevron Corporation 3.48% STX(HB) Seagate Tech 2.78% IMGN Immunogen Inc 2.69% ABBV AbbVie Inc 2.48% XOM Exxon Mobil 1.41% DUK Duke Energy Corporation 0.58% BABA Alibaba Group Holding Ltd -0.84% CBOE CBOE Glbl Mkts Inc -1.23%